Association of baseline and postinfusion biomarkers with safety and efficacy endpoints in patients treated with orvacabtagene autoleucel (orva-cel; JCARH125) in the phase 1/2 evolve study (NCT03430011) Meeting Abstract
| Authors: | Piasecki, J.; Devries, T.; Radhakrishnan, A.; Li, Y.; Heipel, M.; Fox, B. A.; Beckett, V.; Stirner, M. C.; Conte, K.; Doerr, T.; Mailankody, S.; Wong, S. W.; McCarthy, P. L. |
| Abstract Title: | Association of baseline and postinfusion biomarkers with safety and efficacy endpoints in patients treated with orvacabtagene autoleucel (orva-cel; JCARH125) in the phase 1/2 evolve study (NCT03430011) |
| Meeting Title: | 62nd Annual Meeting of the American Society of Hematology (ASH) |
| Journal Title: | Blood |
| Volume: | 136 |
| Issue: | Suppl. 1 |
| Meeting Dates: | 2020 Dec 5-8 |
| Meeting Location: | Virtual |
| ISSN: | 0006-4971 |
| Publisher: | American Society of Hematology |
| Date Published: | 2020-11-05 |
| Language: | English |
| ACCESSION: | WOS:000607547203143 |
| DOI: | 10.1182/blood-2020-137786 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 2 -- Source: Wos |
